RPRX - Royalty Pharma plc
47.48
0.010 0.021%
Share volume: 3,681,476
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.15%
PREVIOUS CLOSE
CHG
CHG%
$47.47
0.01
0.00%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-09-2024 | 08-08-2024 | 11-06-2024 | 02-12-2025 | 05-08-2025 | 11-05-2025 | 02-11-2026 | |
| Total revenue | 567.978 M | 537.267 M | 564.690 M | 593.641 M | 568.247 M | 609.291 M | 621.990 M | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 567.978 M | 537.267 M | 564.690 M | 593.641 M | 568.247 M | 609.291 M | 621.990 M | |
| -5.41% | 5.10% | 5.13% | -4.28% | 7.22% | 2.08% | |||
| Operating expenses | 58.152 M | 55.208 M | 57.220 M | 68.091 M | 161.205 M | 169.234 M | 214.773 M | |
| Selling general and admin | 57.652 M | 54.708 M | 56.720 M | 67.591 M | 110.705 M | 118.734 M | 164.273 M | |
| Research and development | 500.000 K | 500.000 K | 500.000 K | 500.000 K | 50.500 M | 50.500 M | 50.500 M | |
| Total expenses | 72.301 M | 267.637 M | -170.384 M | 232.127 M | 34.065 M | 182.135 M | 233.609 M | |
| 270.17% | -163.66% | 236.24% | -85.32% | 434.67% | 28.26% | |||
| Operating income | 495.677 M | 269.630 M | 735.074 M | 361.514 M | 534.182 M | 427.156 M | 388.381 M | |
| Ebit | -87.923 M | 228.306 M | 844.949 M | 359.425 M | 480.961 M | 500.924 M | 439.008 M | |
| Pretax income | -4.273 M | 194.377 M | 806.358 M | 334.351 M | 433.433 M | 444.211 M | 355.913 M | |
| -4,648.96% | 314.84% | -58.54% | 29.63% | 2.49% | -19.88% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 4.778 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| -100.00% | ||||||||
| Net income | 4.778 M | 194.377 M | 806.358 M | 334.351 M | 433.433 M | 444.211 M | 355.913 M | |
| 3,968.17% | 314.84% | -58.54% | 29.63% | 2.49% | -19.88% |